301089 Stock Overview
Engages in the research, development, production, and sale of chemical synthesis, biological fermentation nucleoside (acid) APIs, and pharmaceutical intermediates in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Tuoxin Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥31.07 |
| 52 Week High | CN¥59.77 |
| 52 Week Low | CN¥25.95 |
| Beta | -0.85 |
| 1 Month Change | -2.30% |
| 3 Month Change | 15.85% |
| 1 Year Change | -47.22% |
| 3 Year Change | -62.30% |
| 5 Year Change | n/a |
| Change since IPO | 7.81% |
Recent News & Updates
Tuoxin Pharmaceutical Group Co.,Ltd. (SZSE:301089) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected
Oct 08
More Unpleasant Surprises Could Be In Store For Tuoxin Pharmaceutical Group Co.,Ltd.'s (SZSE:301089) Shares After Tumbling 28%
Jun 07Shareholder Returns
| 301089 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -8.5% | -3.3% | -2.7% |
| 1Y | -47.2% | -3.1% | 11.8% |
Return vs Industry: 301089 underperformed the CN Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: 301089 underperformed the CN Market which returned 9.7% over the past year.
Price Volatility
| 301089 volatility | |
|---|---|
| 301089 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 301089 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301089's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,550 | Shaohua Yang | www.tuoxinpharm.com |
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research, development, production, and sale of chemical synthesis, biological fermentation nucleoside (acid) APIs, and pharmaceutical intermediates in China and internationally. It offers purine base, pyrimidine base, nucleosides, nucleotide, deoxynucleosides, dehyfrated nucleoside, 2'-modified, Cybinucleoside, and sugar series, and Azvudine intermediate.
Tuoxin Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 301089 fundamental statistics | |
|---|---|
| Market cap | CN¥3.93b |
| Earnings (TTM) | -CN¥72.77m |
| Revenue (TTM) | CN¥415.14m |
9.5x
P/S Ratio-54.0x
P/E RatioIs 301089 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301089 income statement (TTM) | |
|---|---|
| Revenue | CN¥415.14m |
| Cost of Revenue | CN¥381.71m |
| Gross Profit | CN¥33.42m |
| Other Expenses | CN¥106.19m |
| Earnings | -CN¥72.77m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 8.05% |
| Net Profit Margin | -17.53% |
| Debt/Equity Ratio | 0% |
How did 301089 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield-45%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 22:55 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tuoxin Pharmaceutical Group Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|